What sector does Indo Us Biotech Ltd belong to?

Indo Us Biotech Ltd operates in the Fast Moving Consumer Goods sector, specifically the Other Agricultural Products industry, and is listed on the NSE.

What is the current share price of INDOUS?

As of the latest available quote, INDOUS traded at ₹78.24. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of INDOUS?

Indo Us Biotech Ltd has a price-to-earnings (P/E) ratio of about 13.73. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of INDOUS?

The market capitalisation of Indo Us Biotech Ltd is approximately ₹157 Cr.

Is Indo Us Biotech Ltd profitable?

For its latest reported financial year, Indo Us Biotech Ltd recorded a net profit margin of about 10.24%.

Does INDOUS pay a dividend?

Indo Us Biotech Ltd does not currently show a dividend yield in our data.

What is the return on equity (ROE) of INDOUS?

Indo Us Biotech Ltd has a return on equity (ROE) of about 16.90%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of INDOUS?

Over the past 52 weeks, INDOUS has traded between a low of ₹70.00 and a high of ₹159.00.

Indo Us Biotech Ltd

INDOUS NSE Fast Moving Consumer Goods Other Agricultural Products

₹78.24

-1.63%

Delayed · cached 15 min

Fair value analysis

INDOUS

Indo Us Biotech Ltd

₹79.54

Close used for this calculation

₹55.82Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

50/100

Profitability21/25

Returns10/25

Balance Sheet9/25

Efficiency10/25

Growth12/25

Good

Quality radar

Consensus fair value

₹55.82

Above FV

▼ -29.8% against the close used

Model range ₹34.81 – ₹124.75

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹34.81Fair value₹55.82Bull₹124.75

FairClose

52-week traded range

52W low ₹77.4852W high ₹150.72

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Indo Us Biotech Ltd closed at ₹79.54, 42.5% above the consensus fair value of ₹55.82 drawn from 9 valuation models.

Financial DNA score 50/100 — Good. P/E of 31.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹54.98

-30.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹34.81

-56.2%

√(22.5 × EPS × BVPS)

EPS=2.77, BVPS=19.45 · outside Graham range (P/E 31, P/B 4.1) — asset-light, treat as a rough floor

Graham Formula

₹124.75

+56.8%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=20%, FD=7%

P/E Fair Value

₹41.27

-48.1%

EPS × 14.9x (sector P/E)

EPS=2.77, Sector P/E=14.9x

Peter Lynch (PEG)

₹69.25

-12.9%

EPS × Growth% (PEG = 1 is fair)

EPS=2.77, g=25%

EV/EBITDA

₹57.25

-28.0%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=70M

Book Value (P/B)

₹52.99

-33.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=19.45, ROE=16.9%, g=6%, r=10%

Reverse DCF

₹79.54

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 12% | Historical: 25%

Margin of Safety

₹47.96

-39.7%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=63.95, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer